All In Biotech

Drug Trial Radar · NCT06155084

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

A Phase I/II Open-Label Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer in China

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Dec 26, 2023

Primary completion

Mar 2026

Study completion Sep 2026

Sponsor

Lead sponsor
Hinova Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Dec 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this Phase 1 study is to evaluate the safety, PK,and anti-tumor activity of daily oral dosing with HP518,selecting the RP2D of HP518 based on assessments of patients with progressive mCRPC in dose-escalation phase

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • HP518 - Dose EscalationDrug

    Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort

  • HP518 - Dose EscalationDrug

    Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort

  • HP518 -Dose ExpansionDrug

    Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidences of Protocol-defined DLT during the DLT assessment period , characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drugorally administered HP518 (Part 1)Time frame: 28 DAYS
  2. Incidence of Treatment-Emergent Adverse Events characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousnessTime frame: Through study completion, an average of 1 year
  3. Incidence of laboratory abnormalities, characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
  4. Incidence of vital signs abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
  5. Incidence of ECG (PR, QRS, QT, and QTcF intervals) abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
  6. PSA50 response rateTime frame: 12 weeks

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital Of Anhui Medical University

    Hefei, Anhui, China · Recruiting

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Friendship Hospital, Capital Medical University

    Beijing, Beijing Municipality, China · Recruiting

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, China · Recruiting

  • The Second Affiliated Hospital Of Chongqing Medical University

    Chongqing, Chongqing Municipality, China · Recruiting

  • The First Affiliated Hospital Of Xiamen Univeristy

    Xiamen, Fujian, China · Not yet recruiting

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, China · Recruiting

  • The Third Affiliated Hospital of Southern Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The Affiliated Hospital Of Guizhou Medical University

    Guiyang, Guizhou, China · Recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Zhengzhou Central Hospital

    Zhengzhou, Henan, China · Recruiting

  • Tongji Hospital

    Wuhan, Hubei, China · Recruiting

  • Hunan Cancer Hospital

    Changsha, Hunan, China · Recruiting

  • The First Affiliated Hospital Of Nanchang University

    Nanchang, Jiangxi, China · Recruiting

  • Liaoning Cancer Hospital & Institute

    Shenyang, Liaoning, China · Recruiting

  • Shandong Provincial Hospital

    Jinan, Shandong, China · Recruiting

  • The Affiliated Hospital Of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China · Recruiting

  • Shanghai Tenth People's Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • The First Affiliated Hospital Of Xi'An Jiaotong Univeristy

    Xi’an, Shanxi, China · Recruiting

  • Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital

    Chengdu, Sichuan, China · Recruiting

  • West China Hospital Of Sichuan University

    Chengdu, Sichuan, China · Recruiting

  • The Affiliated Hospital Of Southwest Medical University

    Luzhou, Sichuan, China · Recruiting

  • Mianyang Central Hospital

    Mianyang, Sichuan, China · Recruiting

  • The Second Affiliated Hospital Of Kunming Medical University

    Kunming, Yunnan, China · Recruiting

  • The Affiliated Hospital Of School Of Medicine Of Ningbo University

    Ningbo, Zhejiang, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.